What is Leerink Partnrs’ Estimate for MRSN FY2025 Earnings?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Analysts at Leerink Partnrs dropped their FY2025 EPS estimates for Mersana Therapeutics in a research report issued to clients and investors on Monday, March 3rd. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings per share of ($0.63) for the year, down from their prior estimate of ($0.43). The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ FY2026 earnings at ($0.18) EPS.

MRSN has been the subject of a number of other research reports. Wedbush restated an “outperform” rating and set a $4.00 price objective on shares of Mersana Therapeutics in a report on Monday. William Blair initiated coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They set an “outperform” rating on the stock. Finally, Citigroup began coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $4.25.

Mersana Therapeutics Price Performance

Shares of MRSN opened at $0.51 on Wednesday. The stock has a market cap of $63.30 million, a P/E ratio of -0.84 and a beta of 1.39. Mersana Therapeutics has a 1 year low of $0.46 and a 1 year high of $6.28. The stock’s 50-day moving average price is $0.79 and its two-hundred day moving average price is $1.56. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business had revenue of $16.36 million during the quarter, compared to analysts’ expectations of $7.71 million.

Institutional Investors Weigh In On Mersana Therapeutics

Several institutional investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC grew its holdings in shares of Mersana Therapeutics by 8.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock valued at $358,000 after acquiring an additional 14,240 shares in the last quarter. US Bancorp DE bought a new stake in Mersana Therapeutics during the third quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new position in Mersana Therapeutics during the third quarter valued at approximately $34,000. Wells Fargo & Company MN grew its stake in Mersana Therapeutics by 40.3% in the fourth quarter. Wells Fargo & Company MN now owns 67,483 shares of the company’s stock valued at $97,000 after purchasing an additional 19,368 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of Mersana Therapeutics by 28.7% during the 4th quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after purchasing an additional 25,058 shares during the last quarter. Institutional investors own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.